All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Key updates to the classification of AML in the 5th WHO Classification of Haematolymphoid Tumours

Dec 21, 2022
Share:
Learning objective: After reading this article, learners will be able to recall key changes to the classification of acute myeloid leukemia in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours.

The AML Hub is pleased to present a visual abstract highlighting key updates and changes in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Updates are focused on the increased separation between AML types defined by genetic abnormalities and those defined by differentiation, while still recognizing the impact and integration of clinical, molecular/genetic, and pathological factors.


Visual Abstract

To download this visual abstract, click below.

Download here